Pharma Focus Asia
KP - Choose our fully recyclable blister films

Innovent Biologics Receives NMPA Approval of SINTBILO® for Hypercholesterolaemia Treatment

Thursday, August 17, 2023

Innovent Biologics announced the approval of SINTBILO® (tafolecimab injection, an anti-PCSK9 monoclonal antibody) by China's National Medical Products Administration (NMPA).

This approval is specifically for the treatment of adult individuals dealing with primary hypercholesterolaemia, which includes both heterozygous familial and non-familial hypercholesterolaemia, as well as mixed dyslipidemia.

SINTBILO® (tafolecimab injection) is a fully human monoclonal antibody of the IgG2 type. It precisely binds to PCSK9, which results in a reduction in LDL-C levels. This is achieved by stopping PCSK9-mediated endocytosis of low-density lipoprotein receptors (LDLR), leading to better clearance of LDL-C and ultimately lowering its levels.

SINTBILO® (tafolecimab injection) is used alongside dietary measures and in combination with statins or other lipid-lowering therapies. It is intended for adult patients dealing with primary hypercholesterolaemia (including both familial and non-familial cases) as well as mixed dyslipidemia.

The approval is based on findings from three Phase 3 clinical trials (CREDIT-1, CREDIT-2, and CREDIT-4). These trials showed that different dosing plans - 150 mg every 2 weeks, 450 mg every 4 weeks, and 600 mg every 6 weeks - all effectively lower LDL-C, total cholesterol, non-HDL-C, apolipoprotein B, and lipoprotein a levels. These results from the Phase 3 trials offer various treatment options, allowing cardiologists and patients to choose the best fit for their needs.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024